Partners

The FinnGen project is based on exceptionally wide and open co-operation. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, biobanks, international pharmaceutical companies and hopefully hundreds of thousands of Finns.

Project partners

The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.

Coordinating organizations:

University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL acts as the data controller of the register data.

Logos of the coordinating organizations: University of Helsinki/FIMM, HUS/Helsinki Biobank, THL/THL Biobank

Funded by:

Business Finland

and the funding research partners:

AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.

Logos of the companies funding the study (listed above).

In cooperation with the Finnish Biobank cooperative FINBB and these Finnish biobanks:

Auria Biobank
Helsinki Biobank
Hematological Biobank (FHRB Biobank)
Biobank of Eastern Finland
Central Finland Biobank
Northern Finland Biobank Borealis
Finnish Clinical Biobank Tampere
THL Biobank
Blood Service Biobank

The host organisations of the above listed biobanks are described here.

FinnGen in brief

FinnGen is a large public-private partnership aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.